Latus Bio Developed Kidney Gene-Delivery Technology
The Philadelphia-based company engineered a viral capsid that achieved significantly improved tissue targeting in primates.
Updated on Oct. 13, 2026 in Biotech
Live Poll
Are you optimistic that advances in gene therapy will successfully treat complex kidney diseases?
Latus Bio has developed a new gene-delivery technology that demonstrated a fivefold increase in kidney distribution compared to conventional viral vectors. The engineered adeno-associated virus capsid successfully reached 80% of glomeruli in nonhuman primate testing.
Why it matters
Delivering genetic material to specialized kidney cell populations remains a significant technical challenge for current gene therapies. This advancement in tissue-specific delivery could enable new approaches to treating kidney diseases.
The engineered adeno-associated virus capsid achieved five times the kidney distribution of a standard viral vector. During testing, it successfully delivered genetic material to 80% of the glomeruli in the kidneys of adult nonhuman primates.
The players
Latus Bio
A Philadelphia-based biotechnology firm focused on developing gene therapies and engineered capsids for central nervous system and peripheral diseases.
American Society of Nephrology
A professional medical organization that hosts an annual scientific conference known as Kidney Week.
The details
The technology relies on systemic intravenous administration of engineered viral delivery systems to improve tissue specificity. The capsid delivers genetic material directly to diverse cell types including podocytes, mesangial cells, tubular cells, and collecting duct cells.
Timeline
October 21-25, 2026: American Society of Nephrology's Kidney Week 2026 conference.
October 22, 2026: Presentation of research poster TH-PO1123.
The Tech Race
This development represents a major step forward in optimizing adeno-associated virus (AAV) vector delivery systems for specific organs. It addresses a long-standing hurdle in biotech that previously limited the effectiveness of gene therapies intended for complex renal tissue.
While the technology is currently in the preclinical stage, it could eventually pave the way for more effective treatments for chronic kidney conditions. Patients with limited options may eventually benefit from these advanced gene-delivery methods as the company moves toward clinical applications.
The takeaway
This breakthrough demonstrates the potential of engineered capsids to overcome delivery barriers that have historically hindered kidney-targeted gene therapy. Future research will focus on transitioning this technology from preclinical models to the development of human disease treatments.
What happens next
Latus Bio is scheduled to present research findings related to poster TH-PO1123 at the American Society of Nephrology's Kidney Week conference on October 22, 2026.
Further reading
Learn more about the latest industry innovations in our Biotech section.
More information
Researchers and industry professionals can review the American Society of Nephrology abstract search for further details.
Source note: This article includes information reported by MyChesCo.
Live Poll
Are you optimistic that advances in gene therapy will successfully treat complex kidney diseases?
